- Conditions
- Endometrial Serous Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Resection, Triapine
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Depression
- Interventions
- NSI-189 Phosphate, microcrystalline cellulose capsules
- Drug
- Lead sponsor
- Neuralstem Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- GS-0272, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Palo Alto, California • Upland, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- Eplerenone or Placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Miami, Florida • South Miami, Florida
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Detroit, Michigan • Minneapolis, Minnesota + 6 more
- Conditions
- Arginase I Deficiency, Hyperargininemia
- Interventions
- AEB1102
- Drug
- Lead sponsor
- Immedica Pharma AB
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Detroit, Michigan + 3 more
- Conditions
- Prevention of Chikungunya Virus Infection
- Interventions
- mRNA-1944, Placebo
- Biological · Other
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- KRAS p.G12C Mutant Advanced Solid Tumors
- Interventions
- sotorasib, Anti PD-1/L1, Midazolam
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 29 more
- Conditions
- Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)
- Interventions
- Lumasiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 5 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Healthy Adults
- Interventions
- EDG-15400, Placebo
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Celiac Disease
- Interventions
- TIMP-GLIA, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Meridian, Idaho • Indianapolis, Indiana + 5 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
- Interventions
- IDOV-Immune (oncolytic vaccinia virus)
- Biological
- Lead sponsor
- ViroMissile, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • San Antonio, Texas
- Conditions
- Recurrent Glioblastoma
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Anemia, Kidney Disease
- Interventions
- AKB-6548
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Augusta, Georgia • San Antonio, Texas
- Conditions
- Healthy
- Interventions
- ABT-384
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Interventions
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Sunnyvale, California • New York, New York • Houston, Texas
- Conditions
- Anemia, Chronic Kidney Disease
- Interventions
- AKB-6548, Placebo
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 47
- States / cities
- Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
- Conditions
- Alport Syndrome
- Interventions
- lademirsen (SAR339375), Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • New York, New York + 2 more
- Conditions
- Mycosis Fungoides
- Interventions
- Pembrolizumab administered using the Sofusa® DoseConnect™
- Combination Product
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, Tocilizumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • DeLand, Florida + 16 more
- Conditions
- ADHD
- Interventions
- Atomoxetine Hydrochloride
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Carcinoma
- Interventions
- SPI-1620
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
- Interventions
- Placebo, PF-06823859
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more